{"name":"Guangdong Raynovent Biotech Co., Ltd","slug":"guangdong-raynovent-biotech-co-ltd","ticker":"","exchange":"","domain":"guangdongraynovent.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"Metformin Tablets","genericName":"Metformin Tablets","slug":"metformin-tablets","indication":"Other","status":"marketed"},{"name":"ZSP0678-320mg","genericName":"ZSP0678-320mg","slug":"zsp0678-320mg","indication":"Other","status":"phase_1"},{"name":"14C-RAY1225","genericName":"14C-RAY1225","slug":"14c-ray1225","indication":"Other","status":"phase_1"},{"name":"Leritrelvir","genericName":"Leritrelvir","slug":"leritrelvir","indication":"Other","status":"phase_1"},{"name":"RAY1216","genericName":"RAY1216","slug":"ray1216","indication":"Other","status":"phase_3"},{"name":"ZSP0678-180mg","genericName":"ZSP0678-180mg","slug":"zsp0678-180mg","indication":"Other","status":"phase_1"},{"name":"ZSP0678-240mg","genericName":"ZSP0678-240mg","slug":"zsp0678-240mg","indication":"Other","status":"phase_1"},{"name":"ZSP0678-30mg","genericName":"ZSP0678-30mg","slug":"zsp0678-30mg","indication":"Other","status":"phase_1"},{"name":"ZSP1273","genericName":"ZSP1273","slug":"zsp1273","indication":"Treatment of acute uncomplicated influenza A and B in adults and adolescents aged 12 years and older","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Oseltamivir(oral)","genericName":"Oseltamivir(oral)","slug":"oseltamivir-oral","indication":"Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age","status":"marketed"},{"name":"Placebo to Oseltamivir","genericName":"Placebo to Oseltamivir","slug":"placebo-to-oseltamivir","indication":"Treatment of acute uncomplicated influenza A and B infection","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Placebo to ZSP1273","genericName":"Placebo to ZSP1273","slug":"placebo-to-zsp1273","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"RAY1225","genericName":"RAY1225","slug":"ray1225","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Warfarin Sodium Tablets","genericName":"Warfarin Sodium Tablets","slug":"warfarin-sodium-tablets","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"}]}],"pipeline":[{"name":"Metformin Tablets","genericName":"Metformin Tablets","slug":"metformin-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oseltamivir(oral)","genericName":"Oseltamivir(oral)","slug":"oseltamivir-oral","phase":"marketed","mechanism":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.","indications":["Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age","Prophylaxis of influenza A and B in patients ≥1 year of age"],"catalyst":""},{"name":"ZSP0678-320mg","genericName":"ZSP0678-320mg","slug":"zsp0678-320mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-RAY1225","genericName":"14C-RAY1225","slug":"14c-ray1225","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Leritrelvir","genericName":"Leritrelvir","slug":"leritrelvir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo to Oseltamivir","genericName":"Placebo to Oseltamivir","slug":"placebo-to-oseltamivir","phase":"phase_3","mechanism":"This is a Phase 3 clinical trial comparing placebo to oseltamivir (Tamiflu), an antiviral neuraminidase inhibitor used to treat influenza.","indications":["Treatment of acute uncomplicated influenza A and B infection","Prophylaxis of influenza in exposed individuals"],"catalyst":""},{"name":"Placebo to ZSP1273","genericName":"Placebo to ZSP1273","slug":"placebo-to-zsp1273","phase":"phase_3","mechanism":"ZSP1273 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RAY1216","genericName":"RAY1216","slug":"ray1216","phase":"phase_3","mechanism":"RAY1216 is an investigational therapeutic targeting a specific molecular pathway relevant to its indication, currently in phase 3 clinical development.","indications":[],"catalyst":""},{"name":"RAY1225","genericName":"RAY1225","slug":"ray1225","phase":"phase_3","mechanism":"RAY1225 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling pathways.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Warfarin Sodium Tablets","genericName":"Warfarin Sodium Tablets","slug":"warfarin-sodium-tablets","phase":"phase_3","mechanism":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and preventing blood clot formation.","indications":["Atrial fibrillation for stroke prevention","Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention","Mechanical heart valve thromboprophylaxis","Post-myocardial infarction thromboprophylaxis"],"catalyst":""},{"name":"ZSP0678-180mg","genericName":"ZSP0678-180mg","slug":"zsp0678-180mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZSP0678-240mg","genericName":"ZSP0678-240mg","slug":"zsp0678-240mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZSP0678-30mg","genericName":"ZSP0678-30mg","slug":"zsp0678-30mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZSP1273","genericName":"ZSP1273","slug":"zsp1273","phase":"phase_3","mechanism":"ZSP1273 is an influenza virus RNA-dependent RNA polymerase inhibitor that blocks viral replication.","indications":["Treatment of acute uncomplicated influenza A and B in adults and adolescents aged 12 years and older"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNVXpCV25oMmg5aTBBVVZ2cGd1OG9aLUR0aTJJQ2ZHeXQ2TWdHU0gweVlLZ2dXbmVhLXlCaG55X1d2M18yT1J2bk5QbEtXY0JoYWZtbmVrWV96MHVBcW4yOWNaMDhVbWtDTGh1Vkc1UG05em1PaGhVYVRpcFZmbUhCaXBYVU5NcGNXbGljY29fSVUwTzhabmUzSDg3OXk1RS1zc0drUFBPSXJ5WFVyVmZ4RXRVSG92Tk11cFJoVG5sdmFxZTNJdk4wNmQ1VTBGSnNUZ09fbXN4NGpRZEgxYUJzZURPclZ3WnFjNlhaclEwWXBCSGZqdC1QMzNaMXU?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPODR6a0JUUjQ2d3pHa2c0M3gtN2ZRMDVGandaRFJha3VIMjg3OEdjWTRZTk1uMlV4Z3ktQUhXZGgxNW9oYmRPQ29NSlpwYklHenlyOElhTnhHTENKZldhZ1JiZ3RWU19CLW5vRUVGWEpneEs4dGY5V1gxRnhHanA2Ni1qQno5SnkyZG40dWxyYWVzVFM4Z2hKaHJqTlg2OEkzTnhMd0hveW5vdEhiRENMVEFxTlVtV1ZwejdjVHhnVlYtR1lhbDVuRzU3YlVETDR3bjhhZm40LWVNcUpKQVdpY2FHZl9JTWQ2VDVRR19KdjFVd1o5RUQzOERDMkZQcEpLWTNwZVJtcjgzR2ppYUJRS01kMnUxOUpLSDlwWFVHT19EaVZDSFhaS2F5cHpNa0MwZjcwVXY1X0dSejgwNUE?oc=5","date":"2025-01-28","type":"trial","source":"GlobeNewswire","summary":"Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust - GlobeNewswire","headline":"Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQRE0tVHFDTkFjR0pnOEVHY2RxaEFtc3Nna2piVk9FZEg3VjhhOTJSb2FvWGpRdFhJRlFvNVdOV3FfYkJTNGVaSEVGbVpPWjh3REFta3NxM2tSckNkX3dBNVFNWTNUeHdtcVRtdDc0bTMzMVNlTHF6MnNDTUFDcWMxV3dzYmNJbWxUbDJSeGhFdC1wMnU5bG9hZ1h5MDRHM0tWS09WM0xZWkkzUXpOZlNEc25QVmlRNndvZExKZjV0VWFBVlNPTXM1SUJ3em11VzByRUhndk1wRE1ILWVMOUxjXzBXYw?oc=5","date":"2024-09-09","type":"pipeline","source":"prnewswire.com","summary":"Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight - prnewswire.com","headline":"Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNVGhpZEFiUzhvRU5fTEFRVm51dXgyT1E2WDVDZ1UxYTJQdi1UV0w4eVhwSGN4Z2wyUk1nUmdSbGZXcGpzb2RzNTNwNWpTTHZiSUJ2ZFlyMUFxMzFXcDNEZTNnd1k0ZkRTVW11UW01SEJval8wc3RaQmJ4UGJYeFAtOXBQcmxSMWYxX3BEejViZEQ0NU5sdldoNWlCVnRpWEVUZVZ5Mm5ScXdtbGVXR2JmSVhia091d1QyRDZ4UXE2cHlNMXpJaUtKX3FYZDB5ZkZfT3k2dFREMzBRdnlWTnNmOFItYy16VjFVMUNhYUFvMlZpbnBzeUdPWHN2R1YxbEwzU1JlaDhKSldqTWs?oc=5","date":"2024-04-03","type":"pipeline","source":"prnewswire.com","summary":"Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight - prnewswire.com","headline":"Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQWHNuMmYyU0dYeFRna1RXMU02ck5fSklQZllyVFpBREZXNTRGOHJDejZGcGx4RzBFQzhXeDlpalAyOE8xWTlyTmZVUDAyZkhPV2xoNTZlRkRwOHBhUk14VnBOcEhQN3ZOaDdkb3lJZEdsaVRjWk9mS0tDRGU0VDRyQ0JYX0FlSHh5RjFaeWpab0hiNkwwZVk5NHhPNndOTGFPcWRpRjZJUllGVklqNEtZWnZGNVJidWJQbHA5SzYxRmJPT3JSdDZhZ0hKRjJFRmNUek9WUnU4R3NSOWt4bDhWTUI4RzB5WWYxXzRHa3RhbDU2a3UxY3RXYlBLbHNlLXU3bnNwazZEbS15MXFSdEVDaE5ZU0pfb0N2YXB0eWRTN0dQb3lzTTdaek5EMEFGaDVheng3ZFJkYw?oc=5","date":"2023-05-25","type":"trial","source":"prnewswire.com","summary":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPRFFiOHBpZ2p5S3dfc0E3T1hLNlpCVGpIQkxEU05KejcwZ3RsN3B6NndNWTVwa3VuX2dqLXpJUVpkTElWMGdnVWl6c1pXVzc3S0pDZTJOUXdNNV9jUklVVGxCZlBPMEw2bDY4YTJxQngwYTlnUG5QLW12ZVBlb2cyTDRQa0N3NnJmY3JPNHZwU3laUjEyUlY2eC1FSEw0VWJ2Nk9EYW9qOEsyWVVaU1hVazhYMzNZam5zbnpDaVlyd2QzSV8tRVZFMmx3?oc=5","date":"2023-03-24","type":"regulatory","source":"Yicai Global","summary":"Zhongsheng Pharma Falls Despite Conditional Market Approval for Unit’s 3CL Oral Covid Drug - Yicai Global","headline":"Zhongsheng Pharma Falls Despite Conditional Market Approval for Unit’s 3CL Oral Covid Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQbnFfbDU2Vlc0ZW9BcnItOVEta2p2eVBmM3FaaFFERG5CS0tRd2JBd2ZtWXNOd0lXMEZYNG55LS1SaF82T3ltWDFnV2JVQmQzODJjT0RHSGdDOS1LcGJzemZzV2I2cjI1NnVEV0FFSFBKQXhVT05xZlhQQmxWMGNzTjYyOUtnUHczRGdCaTlCQjdjZ3FpbTZyaXZDdktWeWVKc09feVNtbVc5bEVGS09PR29ZSk52Z0t3UkhvbHFDZ2UtWHh3YklxYk45RUo3c1UtOUVZX0FILVozU1MzZTFfREZaYmo1dw?oc=5","date":"2022-08-31","type":"pipeline","source":"prnewswire.com","summary":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight - prnewswire.com","headline":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"marketed":2,"phase_1":6,"phase_3":6},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}